251. Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study.
- Author
-
Valdés, Enrique, Sepúlveda‐Martínez, Alvaro, Candia, Paula, Abusada, Nancy, Orellana, Rodrigo, Manukian, Bárbara, and Cuellar, Eduardo
- Subjects
- *
METFORMIN , *GESTATIONAL diabetes , *INSULIN resistance , *MEDICAL cooperation , *PLACEBOS , *PROBABILITY theory , *RESEARCH , *MULTIPLE regression analysis , *RANDOMIZED controlled trials , *BLIND experiment , *DATA analysis software , *DESCRIPTIVE statistics , *PREGNANCY , *PREVENTION - Abstract
Abstract: Aim: We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR). Methods: A double blind, multicenter, randomized trial was carried out in patients with a history of PIR and pregestational MTF treatment. Groups were allocated either to MTF 1700 mg/day or placebo. Patients were recruited between 12+0 and 15+6 gestational weeks, and treatment was extended until week 36. A multiple logistic regression analysis was applied to determine the relation between the use of metformin and the development of GDM. Results: One hundred and forty one patients were randomized (68 patients in the MTF group and 73 in the placebo group). A total of 30 patients withdrew from the study during follow‐up. Administration of MTF was not associated with a decrease in the incidence of GDM as compared to placebo (37.5% vs 25.4%, respectively;
P = 0.2). Moreover, MTF administration was associated with a significant increase in drug intolerance as compared to placebo (14.3% vs 1.8%, respectively;P = 0.02). Conclusion: The use of MTF is not effective in prevention of GDM in populations with PIR. The use of MTF shows a significantly higher frequency of drug intolerance than placebo. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF